Compile Data Set for Download or QSAR
Report error Found 88 Enz. Inhib. hit(s) with all data for entry = 11369
TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610449(US10053457, Example 44 | 2-(3-Cyclopropyl-pyrazol-...)
Affinity DataIC50: 0.380nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610445(US10053457, Example 41 | 2-(3-Cyclopropyl-pyrazol-...)
Affinity DataIC50: 0.450nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610418(US10053457, Example 14 | 2-(5-Fluoro-indol-1-yl)-1...)
Affinity DataIC50: 0.700nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610443(US10053457, Example 39 | 1-{(R)-2-(2-Hydroxy-ethyl...)
Affinity DataIC50: 1nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610446(US10053457, Example 42 | 1-{(S)-2-Hydroxymethyl-4-...)
Affinity DataIC50: 1nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610432(US10053457, Example 28 | 1-{(R)-2-(2-Hydroxy-ethyl...)
Affinity DataIC50: 1.10nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610414(US10053457, Example 10 | 1-{(R)-2-Hydroxymethyl-4-...)
Affinity DataIC50: 1.10nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610417(US10053457, Example 13 | 2-Benzoimidazol-1-yl-1-{(...)
Affinity DataIC50: 1.20nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610448(US10053457, Example 43 | 2-(3-Ethyl-pyrazol-1-yl)-...)
Affinity DataIC50: 1.20nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610381(US10053457, Example 9 | 1-{(S)-4-[4-(2-Cyclopropyl...)
Affinity DataIC50: 1.30nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610444(US10053457, Example 40 | 2-(3-Ethyl-pyrazol-1-yl)-...)
Affinity DataIC50: 1.60nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610426(US10053457, Example 22 | 1-{(R)-2-Hydroxymethyl-4-...)
Affinity DataIC50: 1.60nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610138(US10053457, Example 4 | 1-{(S)-2-Hydroxymethyl-4-[...)
Affinity DataIC50: 1.80nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610419(US10053457, Example 15 | 1-{(R)-2-Hydroxymethyl-4-...)
Affinity DataIC50: 2.30nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610436(US10053457, Example 32 | 2-(3-Ethyl-[1,2,4]triazol...)
Affinity DataIC50: 2.60nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610439(US10053457, Example 35 | 1-{(R)-2-(2-Hydroxy-ethyl...)
Affinity DataIC50: 2.90nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610068(US10053457, Example 3 | 2-(3-Cyclopropyl-[1,2,4]tr...)
Affinity DataIC50: 3nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610188(US10053457, Example 7 | 2-(3,5-Dimethyl-[1,2,4]tri...)
Affinity DataIC50: 3.10nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610415(US10053457, Example 11 | 1-{(R)-2-Hydroxymethyl-4-...)
Affinity DataIC50: 3.40nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610430(US10053457, Example 26 | 1-{(R)-2-Hydroxymethyl-4-...)
Affinity DataIC50: 3.5nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610429(US10053457, Example 25 | 2-(5-Ethyl-3-methyl-[1,2,...)
Affinity DataIC50: 3.60nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610420(US10053457, Example 16 | 1-{(R)-2-Hydroxymethyl-4-...)
Affinity DataIC50: 3.90nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610160(US10053457, Example 5 | 1-{(S)-2-Hydroxymethyl-4-[...)
Affinity DataIC50: 4nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610425(US10053457, Example 21 | 2-[3-(1-Hydroxy-ethyl)-[1...)
Affinity DataIC50: 4.30nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610434(US10053457, Example 30 | 2-(3-tert-Butyl-[1,2,4]tr...)
Affinity DataIC50: 4.40nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610435(US10053457, Example 31 | 2-(3-Cyclopropyl-[1,2,4]t...)
Affinity DataIC50: 4.40nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610438(US10053457, Example 34 | 1-{(R)-2-(2-Hydroxy-ethyl...)
Affinity DataIC50: 4.5nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610186(US10053457, Example 6 | 1-{(S)-4-[4-(2-Ethoxy-pyri...)
Affinity DataIC50: 4.60nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610431(US10053457, Example 27 | 2-(3,5-Dimethyl-[1,2,4]tr...)
Affinity DataIC50: 5.20nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610433(US10053457, Example 29 | 2-(3-Cyclobutyl-[1,2,4]tr...)
Affinity DataIC50: 5.5nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610441(US10053457, Example 37 | 1-{(R)-2-(2-Hydroxy-ethyl...)
Affinity DataIC50: 5.70nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610421(US10053457, Example 17 | 1-{(R)-2-Hydroxymethyl-4-...)
Affinity DataIC50: 5.90nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610021(US10053457, Example 2 | 2-(3,5-Dimethyl-[1,2,4]tri...)
Affinity DataIC50: 6nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610424(US10053457, Example 20 | 2-(3-Acetyl-[1,2,4]triazo...)
Affinity DataIC50: 6.40nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610020(US10053457, Example 1 | 2-(3-tert-Butyl-[1,2,4]tri...)
Affinity DataIC50: 6.70nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610416(US10053457, Example 12 | 2-(3,5-Dimethyl-[1,2,4]tr...)
Affinity DataIC50: 6.90nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610428(US10053457, Example 24 | 2-(3-Ethyl-5-methyl-[1,2,...)
Affinity DataIC50: 7.60nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610440(US10053457, Example 36 | 1-{(R)-2-(2-Hydroxy-ethyl...)
Affinity DataIC50: 8nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610442(US10053457, Example 38 | 2-(3-Difluoromethyl-[1,2,...)
Affinity DataIC50: 8.60nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610196(US10053457, Example 8 | 1-{(S)-4-[4-(2-Cyclopropyl...)
Affinity DataIC50: 10nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610437(US10053457, Example 33 | 2-(5-Ethyl-[1,2,4]triazol...)
Affinity DataIC50: 27nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610445(US10053457, Example 41 | 2-(3-Cyclopropyl-pyrazol-...)
Affinity DataIC50: 30.2nMAssay Description:Stock solutions of test compounds are made up at a concentration of 10 mM in DMSO, and serially diluted in PBS containing 0.5% BSA to concentrations ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610444(US10053457, Example 40 | 2-(3-Ethyl-pyrazol-1-yl)-...)
Affinity DataIC50: 32.7nMAssay Description:Stock solutions of test compounds are made up at a concentration of 10 mM in DMSO, and serially diluted in PBS containing 0.5% BSA to concentrations ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610427(US10053457, Example 23 | 1-{(R)-2-Hydroxymethyl-4-...)
Affinity DataIC50: 35nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610448(US10053457, Example 43 | 2-(3-Ethyl-pyrazol-1-yl)-...)
Affinity DataIC50: 40.3nMAssay Description:Stock solutions of test compounds are made up at a concentration of 10 mM in DMSO, and serially diluted in PBS containing 0.5% BSA to concentrations ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610423(US10053457, Example 19 | 1-{(R)-2-Hydroxymethyl-4-...)
Affinity DataIC50: 42nMAssay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610443(US10053457, Example 39 | 1-{(R)-2-(2-Hydroxy-ethyl...)
Affinity DataIC50: 46.3nMAssay Description:Stock solutions of test compounds are made up at a concentration of 10 mM in DMSO, and serially diluted in PBS containing 0.5% BSA to concentrations ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610446(US10053457, Example 42 | 1-{(S)-2-Hydroxymethyl-4-...)
Affinity DataIC50: 59.7nMAssay Description:Stock solutions of test compounds are made up at a concentration of 10 mM in DMSO, and serially diluted in PBS containing 0.5% BSA to concentrations ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610435(US10053457, Example 31 | 2-(3-Cyclopropyl-[1,2,4]t...)
Affinity DataIC50: 73.8nMAssay Description:Stock solutions of test compounds are made up at a concentration of 10 mM in DMSO, and serially diluted in PBS containing 0.5% BSA to concentrations ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM610430(US10053457, Example 26 | 1-{(R)-2-Hydroxymethyl-4-...)
Affinity DataIC50: 74.2nMAssay Description:Stock solutions of test compounds are made up at a concentration of 10 mM in DMSO, and serially diluted in PBS containing 0.5% BSA to concentrations ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/31/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 88 total ) | Next | Last >>
Jump to: